These findings suggest that HDAC3 inhibitors, possibly in combination with STING activators, could be a promising therapeutic strategy to improve immune response and inhibit tumor progression in endometrial cancer (Figure 3) (51). Here, HDAC3 is linked to endometrial cancer.